Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens

被引:53
作者
Dudley, ME
Roopenian, DC
机构
[1] Jackson Laboratory, Bar Harbor
关键词
D O I
10.1084/jem.184.2.441
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Most chemically induced tumors of mice express unique antigens that call be recognized by cytotoxic T lymphocytes (CTL) and thereby mediate tumor rejection. The number of different antigens expressed by a single tumor and their interplay during immunization and rejection are largely unexplored. We used CTL clones specific to individual tumor antigens to examine the number and distribution of CTL antigens expressed by cell lines derived from 3-methylcholanthrene-induced sarcomas of (C57BL/6J x SPRET/Ei)F-1 mice. Each tumor cell line expressed one or more antigens that were unique, that is, not detected on cell lines from independent sarcomas. Immunoselection against an immunodominant antigen produced both major histocompatibility complex class I antigen and unique tumor antigen loss variants. Immunization of mice with antigen-negative immunoselected variants resulted in CTL that recognized additional antigens that wire also expressed by the progenitor tumor. Some CTL recognized additional unique tumor antigen(s); other CTL recognized a shared antigen expressed not only by the immunizing cell line, but also by independent sarcoma cell lines and untransformed myoblastoid cell Lines. CTL that recognized the shared antigen were also recovered from mice immunized in vivo with an untransformed myoblastoid cell line. These findings support a model of immunodominance among chemically induced tumor antigens in which shared antigens are masked by unique immunodominant antigens.
引用
收藏
页码:441 / 447
页数:7
相关论文
共 28 条
[1]  
BARTH RJ, 1990, J IMMUNOL, V144, P1531
[2]  
BASOMBRIO MA, 1970, CANCER RES, V30, P2458
[3]  
BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.iy.12.040194.002005
[4]  
CHOU TK, 1987, J IMMUNOL, V139, P2103
[5]  
DUDLEY ME, 1995, ONCOGENE, V11, P517
[6]   MECHANISMS OF ANTI-TUMOR ACTION OF CORYNEBACTERIUM-PARVUM .1. POTENTIATED TUMOR-SPECIFIC IMMUNITY AND ITS THERAPEUTIC LIMITATIONS [J].
DYE, ES ;
NORTH, RJ ;
MILLS, CD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1981, 154 (03) :609-620
[7]  
FRASSANITO MA, 1994, CANCER RES, V54, P4424
[8]   IDENTIFICATION OF A HUMAN-MELANOMA ANTIGEN RECOGNIZED BY TUMOR-INFILTRATING LYMPHOCYTES ASSOCIATED WITH IN-VIVO TUMOR REJECTION [J].
KAWAKAMI, Y ;
ELIYAHU, S ;
DELGADO, CH ;
ROBBINS, PF ;
SAKAGUCHI, K ;
APPELLA, E ;
YANNELLI, JR ;
ADEMA, GJ ;
MIKI, T ;
ROSENBERG, SA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (14) :6458-6462
[9]   DELETION MAPPING BY IMMUNOSELECTION AGAINST THE H-Y HISTOCOMPATIBILITY ANTIGEN FURTHER RESOLVES THE SXR(A) REGION OF THE MOUSE Y-CHROMOSOME AND REVEALS COMPLEXITY OF THE HYA LOCUS [J].
KING, TR ;
CHRISTIANSON, GJ ;
MITCHELL, MJ ;
BISHOP, CE ;
SCOTT, D ;
EHRMANN, I ;
SIMPSON, E ;
EICHER, EM ;
ROOPENIAN, DC .
GENOMICS, 1994, 24 (01) :159-168
[10]  
KITAJIMA T, 1994, CANCER IMMUNOL IMMUN, V38, P372